LY 303511

LY303511 is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks K+ currents (IC50=64.6±9.1 μM) in MIN6 insulinoma cells.

Product Specifications

CAS Number

[154447-38-8]

UNSPSC

12352005

Hazard Statement

H302

Target

Potassium Channel; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Membrane Transporter/Ion Channel

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/LY-303511.html

Solubility

10 mM in DMSO

Smiles

O=C1C=C(N2CCNCC2)OC3=C(C4=CC=CC=C4)C=CC=C13

Molecular Formula

C19H18N2O2

Molecular Weight

306.36

Precautions

P264-P270-P330-P501

References & Citations

[1]Bodenstine TM, et al. Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition. Cancer Res. 2010 Dec 1;70 (23) :10002-11.|[2]Shenoy K, et al. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res. 2009 Mar 1;69 (5) :1941-50.|[3]El-Kholy W, Macdonald PE, Lin JH, The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K (V) currents via a direct mechanism. FASEB J. 2003 Apr;17 (6) :720-2.|[4]Kristof AS, et al. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR) - and non-mTOR-dependent mechanisms. J Pharmacol Exp Ther. 2005 Sep;314 (3) :1134-43.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Int J Mol Sci. 2023 Jul 28;24 (15) :12079.|bioRxiv. 2025 Nov 8.|Cancer Cell Int. 2021 Jun 5;21 (1) :291.|Proc Natl Acad Sci U S A. 2024 Nov 19;121 (47) :e2405534121.